HART NYLI Healthy Hearts ETF

On February 3, 2022, Biostage, Inc. (the “Company”) posted to its website a video containing one of the two webinars it hosted on January 27, 2022, along with question and answer sessions from both webinars. Such webinars allowed investors to meet its founder and new Interim CEO and Chairman, David Green, and during the webinars, Mr. Green reviewed the Company’s plans for its approved clinical trial, raising capital and uplisting to NASDAQ and each included a question and answer session.

A link to the video is https://vimeo.com/671485170.

Forward-Looking Statements 

This Current Report on Form 8-k includes statements that are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include, but are not limited to, statements relating to the litigation matters described above, our defense of such matters and the impact of such matters, including on our financial condition and operations. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this Form 8-k, including, among other things, factors described under the heading "Item 1A. Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 or described in the Company's other public filings. The forward-looking statements in this Form 8-k speak only as of the date of this Form 8-k. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.